VYNE Therapeutics Inc. VYNE
At closeJul 27, 2026, 4:00 PM EDT
After hours · Jul 27, 4:00 PM ET
- YTD
- +4,824.14%
- 1 year
- +1,662.96%
- Market cap
- 19.07M
- Revenue (ttm)
- 493.00K
- EPS (ttm)
- 3.29
- Shares out
- 14.75M
- P/E ratio
- 0.78
- Forward P/E
- -2.95
- YTD return
- +4824.14%
- 1-year return
- +1662.96%
- Volume
- 93.26K
- Avg volume
- 87.38K
- Open
- 25.50
- Previous close
- 28.56
- Day's range
- 23.37 – 28.72
- 52-week range
- 1.57 – 3.43
- Beta
- 1.35
- Price target
- 6.19 (-78.3%)
- Earnings date
- Aug 14, 2024
2Y 0.00 (0.00%)
Key statistics
- Enterprise value
- -33.18M
- PEG ratio
- 0.00
- Price / sales
- 76.90
- Price / book
- 0.60
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 6.10%
- Free cash flow
- 0
- Total cash
- 70.19M
- Total debt
- 123.00K
- Return on equity
- -90.47%
- Short % of float
- 0.44%
- 50-day average
- 2.68
- 200-day average
- 2.31
Analyst view
- Target (low)
- 5.00
- Target (mean)
- 6.19
- Target (high)
- 8.00
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.24 | -0.29 | -0.05 | -20.83% |
| Aug 14, 2024 | Jun 1, 2024 | -0.19 | -0.22 | -0.03 | -15.79% |
| Aug 14, 2024 | Jun 1, 2024 | -0.19 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.24 | -0.15 | +0.09 | +37.50% |
| May 9, 2024 | Mar 1, 2024 | -0.24 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.50 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 18, 2024 | BTIG | init | — | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About VYNE Therapeutics Inc.
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vynetherapeutics.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on VYNE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DOMZALSKI DAVID T | Chief Executive Officer | Stock Award(Grant) | Nov 28, 2024 | 500,597 |
| HARSCH MUTYA FONTE | General Counsel | Stock Award(Grant) | Dec 28, 2023 | 149,435 |
| LEPORE PATRICK G | Director | Purchase | Nov 14, 2023 | 36,472 |
| STUART IAIN A | Officer | Stock Award(Grant) | Dec 28, 2023 | 133,898 |
| ZERONDA TYLER | Chief Financial Officer | Stock Award(Grant) | Dec 28, 2023 | 131,837 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Eventide Asset Management LLC | 9.45% | 1,394,336 | 3.58M | Sep 29, 2024 |
| Cormorant Asset Management, LP | 9.45% | 1,394,336 | 3.58M | Sep 29, 2024 |
| Citadel Advisors Llc | 8.05% | 1,187,413 | 3.05M | Sep 29, 2024 |
| DSC Advisors, L.P. | 4.72% | 696,465 | 1.79M | Sep 29, 2024 |
| Palo Alto Investors Lp | 3.02% | 445,434 | 1.14M | Sep 29, 2024 |
| Vanguard Group Inc | 3.01% | 443,518 | 1.14M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.53% | 373,319 | 959.43K | Sep 29, 2024 |
| Mutual Fund Ser Tr-AlphaCentric LifeSci Healthcare Fund | 1.82% | 268,485 | 690.01K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 70,144 | 180.27K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.47% | 69,195 | 177.83K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.24% | 35,547 | 91.36K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 21,485 | 55.22K | Oct 30, 2024 |